Related Experiment Video
Updated: Aug 7, 2026

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 18, 2011
Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that
1Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center; 915 Camino de Salud, NE. Albuquerque, New Mexico, NM 87131, USA.
Abstract:
BRCA2 is a tumor suppressor gene involved in mammary tumorigenesis. Although important functions have been assigned to a few conserved domains of BRCA2, little is known about the longest internal conserved domain encoded by exons 14-24. We identified a novel protein, designated BCCIPalpha, that interacts with part of the internal conserved region of human BRCA2. Human BCCIP represents a family of proteins that are evolutionarily conserved, and contain three distinct domains: an N-terminus acidic domain (NAD) of 30-60 amino acids, an internal conserved domain (ICD) of 180-220 amino acids, and a C-terminus variable domain (CVD) of 30-60 amino acids. The N-terminal half of the human BCCIP ICD shares moderate homology with regions of calmodulin and M-calpain, suggesting that BCCIP may also bind Ca. Human cells express both a longer, BCCIPalpha, and a shorter, BCCIPbeta, form of the protein, which differ in their CVD. BCCIP is a nuclear protein highly expressed in testis. Although BCCIPbeta expression is relatively consistent in cancer cells, the expression of BCCIPalpha varies in cancer cell lines. The BCCIPalpha gene is located at chromosome 10q25.3-26.2, a region frequently altered in brain and other cancers. Furthermore, expression of BCCIPalpha inhibits breast and brain cancer cell growth, but fails to inhibit HT1080 cells and a non-transformed human skin fibroblast. These results suggest that BCCIPalpha is an important cofactor for BRCA2 in tumor suppression.
Insights
Researchers discovered BCCIPalpha, a novel protein interacting with BRCA2. BCCIPalpha acts as a tumor suppressor, inhibiting breast and brain cancer cell growth, suggesting its role as a BRCA2 cofactor.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- BRCA2 is a crucial tumor suppressor gene implicated in mammary tumorigenesis.
- The longest internal conserved domain of BRCA2 (exons 14-24) remains understudied.
- Understanding BRCA2's interactions is vital for cancer research.
Purpose of the Study:
- To identify novel proteins interacting with BRCA2's internal conserved region.
- To characterize the newly identified protein, BCCIPalpha, and its functional role.
- To investigate BCCIPalpha's potential involvement in tumor suppression.
Main Methods:
- Protein interaction studies to identify BCCIPalpha.
- Analysis of BCCIP protein family conservation and domain structure.
- Gene expression analysis in various cell lines and cancer tissues.
- Functional assays assessing BCCIPalpha's effect on cancer cell growth.
Main Results:
- A novel protein, BCCIPalpha, was identified, interacting with BRCA2.
- BCCIPalpha is an evolutionarily conserved protein with distinct domains (NAD, ICD, CVD).
- BCCIPalpha expression varies in cancer cell lines and is located on chromosome 10q25.3-26.2, a region altered in cancers.
- BCCIPalpha expression inhibits breast and brain cancer cell proliferation.
Conclusions:
- BCCIPalpha is a nuclear protein, highly expressed in testis.
- BCCIPalpha's interaction with BRCA2 suggests a role as a cofactor in tumor suppression.
- BCCIPalpha's differential expression and growth inhibitory effects highlight its significance in cancer biology.
Related Concept Videos
Negative Regulator Molecules
Inhibition of Cdk Activity
Abnormal Proliferation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Intrinsic Apoptotic Pathway
Inhibition of CDK Activity

